Wegovy vs Mounjaro: The Complete UK Comparison Guide
Ozempic and Wegovy vs Mounjaro: Understanding the Key Mechanisms
When researching Ozempic and Wegovy options, it's crucial to understand that Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. Mounjaro, by contrast, uses tirzepatide—a dual agonist targeting both GIP and GLP-1 receptors simultaneously. This fundamental difference means each prescription-only medicine works through distinct pathways to support appetite control and satiety. Both mechanisms have shown effectiveness in clinical trials, but the dual-receptor approach of Mounjaro represents a different therapeutic strategy compared to Wegovy's single GLP-1 focus.
The practical implications of these mechanisms become apparent in how each treatment affects your eating patterns and food cravings. Wegovy's GLP-1 action primarily works on brain appetite centres to reduce hunger and promote feelings of fullness after smaller meals. Mounjaro's additional GIP receptor activity may influence glucose metabolism and insulin sensitivity alongside appetite regulation. Neither approach is inherently superior—your prescriber at EverydayMeds can evaluate which mechanism aligns better with your medical profile and weight management goals during the clinical assessment process.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
Understanding the cost implications when comparing Ozempic and Wegovy alternatives requires examining both treatments' pricing structures at EverydayMeds. Wegovy follows a five-dose escalation from 0.25mg (£79.99) through to 2.4mg maintenance (£209.99), with our Getting Started bundles like the Intro Duo providing two months' initial supply for £169.99. New customers can apply code FIRST40 at checkout, whilst returning patients use DOSE25 to reach these final prices. Our Ultimate Stability Trio offers three months of 2.4mg maintenance doses for £649.99, ensuring uninterrupted supply during the crucial maintenance phase.
Mounjaro pricing reflects its six-dose escalation schedule from 2.5mg through to 15mg, though direct price comparisons can be misleading due to different dosing frequencies and titration schedules. Both treatments require careful dose escalation—you cannot skip steps with either option. The total cost of reaching maintenance varies between the two, but both represent significant investments in long-term weight management. Our clinical team, registered with GPhC #9012878, ensures you receive authentic products with proper cold-chain handling, justifying the prescription-only medicine pricing through safety and efficacy ensures.
Clinical Evidence: Ozempic and Wegovy vs Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent weight management support across different populations, including those with type 2 diabetes achieving around 9.6% weight reduction in STEP 2. Importantly, the SELECT trial showed a 20% reduction in major cardiovascular events, indicating benefits beyond weight management.
Mounjaro's SURMOUNT trials have shown their own impressive results, though direct comparison of percentage weight loss figures would be inappropriate given different trial designs, populations, and endpoints. Both treatments have undergone rigorous MHRA evaluation and received approval for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. The evidence supports both mechanisms as effective tools when used as part of comprehensive weight management programmes including dietary modification and increased physical activity.
How Wegovy Works in Ozempic and Wegovy Comparisons
Wegovy functions as a GLP-1 receptor agonist, essentially mimicking incretin hormones that naturally regulate appetite and blood sugar. When injected once weekly using the FlexTouch pen, semaglutide binds to GLP-1 receptors in your brain's appetite centres, potentially reducing hunger sensations and food cravings. The medication may help you feel satisfied with smaller portions, supporting the calorie deficit necessary for weight management. This mechanism works synergistically with behavioural changes—the reduced appetite makes it easier to adhere to a reduced-calorie diet, whilst the increased satiety helps maintain these changes long-term. The prescription-only medicine status ensures proper medical oversight, as individual responses can vary and dose adjustments may be needed based on tolerability and effectiveness.
EverydayMeds Ordering Process for Both Treatments
Accessing either Wegovy or Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for these prescription-only medicines. Our qualified prescribers review your medical history, current medications, and weight management goals within standard 3 working days (express 24-hour service available). Once approved, your chosen treatment ships via next-day delivery using specialised cold-chain packaging to maintain the 2-8°C temperature requirements. Our GPhC-registered pharmacy (#9012878) ensures every pen meets MHRA standards for authenticity and storage integrity. The process includes clear instructions for dose escalation, injection technique, and what to expect during your first weeks of treatment.
Storage and Practical Considerations: Wegovy vs Mounjaro
A significant practical advantage when comparing Ozempic and Wegovy against Mounjaro lies in storage flexibility—Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day limit. This makes Wegovy particularly suitable for frequent travellers or those with limited fridge space. Both use pre-filled pens with dose counters, though Wegovy's FlexTouch system has been refined over years of diabetes treatment experience. The weekly injection schedule applies to both treatments, typically administered on the same day each week. Dose escalation cannot be rushed with either option—the gradual increases help minimise gastrointestinal side effects whilst allowing your body to adapt to the medication's appetite-suppressing effects.
Ozempic and Wegovy Research: Why This Comparison Matters
Many patients researching Ozempic and Wegovy discover that Ozempic itself isn't licensed for weight management in the UK—it's specifically approved for type 2 diabetes treatment. This regulatory distinction makes Wegovy vs Mounjaro the appropriate comparison for weight management purposes. Both treatments have received NICE recommendations (TA875 for Wegovy) with specialist weight management support, validating their role in comprehensive obesity treatment. The choice between single GLP-1 (Wegovy) and dual GIP/GLP-1 (Mounjaro) represents different approaches to metabolic intervention.
Understanding this distinction helps explain why EverydayMeds focuses on providing both Wegovy and Mounjaro rather than promoting off-label alternatives. Our clinical team recognises that optimal treatment selection depends on individual factors including previous medication responses, comorbidities, and lifestyle considerations. The prescription-only medicine framework ensures appropriate medical oversight throughout your weight management journey, whether you choose the established GLP-1 pathway or the newer dual-agonist approach.
Making Your Choice: Expert Support at EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which treatment aligns with your specific circumstances and medical history. Our clinical assessment evaluates factors beyond simple BMI calculations, considering your previous weight management attempts, current medications, and individual risk factors. New customers can use code FIRST40 whilst returning patients apply DOSE25 at checkout to access our competitive pricing across both treatment options. The decision shouldn't be made in isolation—our qualified prescribers provide the medical expertise necessary to navigate these sophisticated weight management tools safely. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment and receive personalised guidance on whether Wegovy's single-receptor approach or Mounjaro's dual-agonist mechanism better suits your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
